1 / 13

Xeloda: the partner of choice for the treatment of metastatic CRC

Xeloda: the partner of choice for the treatment of metastatic CRC. Jim Cassidy Beatson Oncology Centre Glasgow, UK. Synergistic activity with Xeloda in preclinical models. 1 Sawada N et al. Clin Cancer Res 1999;5:2948–53 2 Cassidy J et al. J Clin Oncol 2004;22:2084–91

molimo
Download Presentation

Xeloda: the partner of choice for the treatment of metastatic CRC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Xeloda: the partner of choice for the treatment of metastatic CRC Jim Cassidy Beatson Oncology CentreGlasgow, UK

  2. Synergistic activity withXeloda in preclinical models 1Sawada N et al. Clin Cancer Res 1999;5:2948–53 2Cassidy J et al. J Clin Oncol 2004;22:2084–91 3Tewes M et al. Ann Oncol 2003;14:1442-8 4Shen B-Q et al. Proc Am Assoc Cancer Res 2004;45 (Abst 2203) 5Ishitsuka H. Invest New Drugs 2000;18:343–54 6Tanaka Y et al. Proc Am Assoc Cancer Res 2003;44 (Abst 4678)

  3. 1 8 15 21 Day Oxaliplatin130mg/m2 (2-hour infusion) Xeloda1000mg/m2 twice daily Day 1 (pm)–15 (am) Rest Repeat cycle at day 22 Standard XELOX regimen • Developed from phase I and II trial program1,2 1Díaz-Rubio E et al. Ann Oncol 2002;13:558–65 2Cassidy J et al. J Clin Oncol 2004;22:2084–91

  4. In MCRC, XELOX is comparable to 5-FU-based regimens: response rates Response (%) 60 50 40 30 20 10 0 XELOX (n=96)1 XELOX (n=45)2 DI XELOX (n=44)2 FOLFOX (n=267)3 FOLFOX (n=210)4 XELOX (n=35)5 FOLFOX (n=41)5 CAPOX (n=238)6 FUFOX (n=230)6 XELOX (n=128)7 Oxaliplatin/ 5-FU (TTD) (n=132)7 1Cassidy J et al. J Clin Oncol 2004;22:2084–91; 2Scheithauer W et al. J Clin Oncol 2003;21:1307–123Goldberg R et al. J Clin Oncol 2004;22:23–30; 4de Gramont A et al. J Clin Oncol 2000;18:2938–475Hochster HS et al. Proc ASCO 2005 (Abst 3515); 6Arkenau HT et al. Proc ASCO 2005 (Abst 3507) 7Sastre J et al. Proc ASCO 2005 (Abst 3524)

  5. In MCRC, XELOX is comparable to 5-FU-based regimens: TTP Median TTP (months) 12 10 8 6 4 2 0 XELOX (n=96)1 XELOX (n=45)2 DI XELOX (n=44)2 FOLFOX (n=267)3 FOLFOX (n=210)4 CAPOX (n=238)5 FUFOX (n=230)5 1Cassidy J et al. J Clin Oncol 2004;22:2084–91; 2Scheithauer W et al. J Clin Oncol 2003;21:1307–123Goldberg R et al. J Clin Oncol 2004;22:23–30; 4de Gramont A et al. J Clin Oncol 2000;18:2938–475Arkenau HT et al. Proc ASCO 2005 (Abst 3507)

  6. XELOX is well tolerated versus 5-FU-based regimens: phase III evaluation in MCRC 1Sastre J et al. Proc ASCO 2005 (Abst 3524) 2Arkenau HT et al. Proc ASCO 2005 (Abst 3507) 3Ducreux M et al. Proc ASCO 2005 (Abst 3596)

  7. XELOX (n=48) FOLFOX (n=49) bFOL (n=50) XELOX-Avastin (n=72) FOLFOX-Avastin (n=71) bFOL-Avastin (n=70) Limited additional toxicities with Avastin (grade 3/4 adverse events*) Patients (%) TREE-1 TREE-2 HFS Diarrhea Neutropenia Neuro-toxicity Bleeding Venousthromboembolism Hypertension *First 12 weeks Hochster HS et al. Proc ASCO 2005 (Abst 3515)

  8. 3-weekly XELIRI regimen 1 8 15 21 Day Irinotecan250mg/m2 (90-minute infusion) Xeloda1000mg/m2 twice daily Day 1 (pm)–15 (am) Rest Repeat cycle at day 22 Patt YZ et al. Ann Oncol 2004;15(Suppl. 3):iii88 (Abst 238P)

  9. 30 25 20 15 10 5 0 Consistently high activity with first-line 3-weekly XELIRI Response rate (%) Median TTP (months) Median survival (months) 60 50 40 30 20 10 0 10 8 6 4 2 0 XELIRI (n=52)1 XELIRI (n=68)2 XELIRI (n=37)3 XELIRI (n=52)1 XELIRI (n=68)2 XELIRI (n=37)3 XELIRI (n=52)1 XELIRI (n=37)3 1Patt YZ et al. Ann Oncol 2004;15(Suppl. 3):iii88 (Abst 238P) 2Bajetta E et al. Cancer 2004;100:279–87; 3Borner MM et al. Ann Oncol 2005;16:282–8

  10. Response rates: XELIRI compares favorably with 5-FU/LV/irinotecan Response (%) 60 50 40 30 20 10 0 XELIRI (n=52)1 XELIRI (n=68)2 XELIRI (n=37)3 XELIRI (n=36)4 XELIRI (n=45)5 XELIRI (n=38)6 FOLFIRI (n=145)7 FOLFIRI (n=109)8 1Patt YZ et al. Ann Oncol 2004;15(Suppl. 3):iii88 (Abst 238P); 2Bajetta E et al. Cancer 2004;100:279–87 3Borner MM et al. Ann Oncol 2005;16:282–8; 4Ahn J et al. Proc ASCO 2005 (Abst 3714)5Garcia-Alfonso P et al. Proc ASCO 2005 (Abst 3540); 6El Rayes BF et al Proc ASCO 2005 (Abst 3677) 7Douillard JY et al. Lancet 2000;355:1041–7; 8Tournigand C et al. J Clin Oncol 2004;22:229–37

  11. Safety of Xeloda- and 5-FU-based combinations with irinotecan 1Patt YZ et al. Ann Oncol 2004;15(Suppl. 3):iii88 (Abst 238P); 2Borner M et al. Ann Oncol 2005;16:282–83Garcia-Alfonso P et al. Proc ASCO 2005 (Abst 3540); 4Ahn J et al. Proc ASCO 2005 (Abst 3714)5Köhne C et al. Proc ASCO 2005 (Abst 3525); 6Douillard JY et al. Lancet 2000;355:1041–7

  12. XELIRI: upcoming evidence

  13. Xeloda is an effective, well tolerated combination partner in MCRC • Xeloda is an effective combination partner • Xeloda is a safe combination partner • Xeloda-based combinations are more convenientand less complex than with 5-FU/LV • avoid the use of central venous devices and pumps • simplify increasingly complex regimens

More Related